N

Northeast Research Institute | Fleming Island, FL

Research site
(Unclaimed)
Location
1635 Eagle Harbor Parkway, Suite 6, Fleming Island, Florida, United States of America
Site insights

Top conditions

Diabetes Mellitus (10 trials)

Type 2 Diabetes Mellitus (9 trials)

Obesity (9 trials)

Overweight (6 trials)

Kidney Diseases (3 trials)

Top treatments

Semaglutide
Retatrutide
Tirzepatide
LY3305677
Sugar
Metformin
LY3841136
NN0519-0130
LY3298176

Parent organization

This site is a part of Northeast Research Institute

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

15 of 17
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
Locations recently updated
A Chronic Weight Management Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: LY3305677
Drug: LY3841136

This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 differen...

Not yet enrolling
Obesity
Drug: NNC0519-0130
Drug: Tirzepatide

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 dia...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine...

Enrolling
Obesity
Drug: Semaglutide
Drug: Cagrilintide

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 s...

Active, not recruiting
Obesity
Drug: Semaglutide
Drug: Placebo semaglutide

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participan...

Active, not recruiting
Overweight
Type 2 Diabetes Mellitus
Drug: Cagrilintide
Drug: Placebo cagrilintide

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (m...

Enrolling
Type 2 Diabetes
Drug: Insulin glargine
Drug: IcoSema

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec take...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: IcoSema
Drug: Insulin icodec

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesit...

Enrolling
Chronic Kidney Disease
Obesity
Drug: Semaglutide
Drug: Placebo
Locations recently updated

The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participa...

Active, not recruiting
Diabetes
Type 1 Diabetes
Drug: Insulin Degludec
Drug: Insulin Efsitora Alfa

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety...

Enrolling
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3305677
Locations recently updated

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ina...

Begins enrollment this month
Diabetes Type 2
Drug: Placebo
Drug: Retatrutide

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ren...

Enrolling
Type 2 Diabetes
Drug: Placebo
Drug: Retatrutide

The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints f...

Enrolling
Type 2 Diabetes
Device: Duodenal Mucosal Resurfacing (Sham)
Device: Duodenal Mucosal Resurfacing (DMR)

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Ziltivekimab C
Drug: Placebo (Ziltivekimab B)

Trial sponsors

Novo Nordisk logo

Novo Nordisk (10 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems